biogen, celgene, gilead. these are the top holdings. >> biotechs in a bubble, a lot of these companies have no earnings, which i get a. lot are biotech in name only. celgene, gilead, amgen, looking at how pristine the balance is, no debt. i don't think those are necessarily in. i think cellgene continues to hire. gilead, amgen. that's a real story we talked about. >> if you seen this news, celgene announced in the new england journal, it's gaining acceptance. that's to me often been time to fade somebody. few look at the ibb, the rsi, the relative strength indicator, momentum. everything jeffrey was saying. are you in a third place where we are trading 81, 82, 83, which is way overbought territory. it's pulled back every single time. they have been pullbacks to buy. jumping in on monday to buy these stocks after huge runs, i think you have to be cautious. >> i spoke about this a lot. when you go with the ibb, you go with the top holdings on it. look at my clearance, clo vis pharmaceuticals down 52%. this year

biogen was one of the best performers in the s&p 500 after the experimental alzheimer's drug we told you about last night showed in a study it significantly slowed mental decline. shares jumped nearly 10% on the news. meg tirrell has more on this possible breakthrough. >> reporter: the expectations were sky high and today, biogen exceeded them giving hope for a disease with no good treatment options. in a small study reported today, biogen's experimental alzheimer's drug known as bib 37 reduced plaque build-ups in the brain associated with t disease and also shows significant benefits on two measures of cognition. slowing the declines in memory loss and thinking clearly compared with the placebo. >> did better than expected overall and what's really interesting is this class of anti-bodies for alzheimer's disease in the past has had very mixed results and most of the drugs actually failed. but today's result is great for patience. >> reporter: the positive efficacy results were a surprise because the study was in the early phases primarily for safety. show side effects including clea

shares of biogenic are surging. the company's extremity drug for alzheimer's slowed progression of the disease. it reduces the protein that causes plaque in the brain and reduced cognitive decline. the results are positive enough that biogen is escaping mid-stage testing and will move into final stage trials. one year into the conflict in eastern ukraine and the sihgns of war are everywhere. ryan chilcote visited donetsk inside separatist territory where he witnessed how a fragile cease-fire failed to lift the fog of war. ryan: the fast-moving cars should have been a clue. >> small arms fire there. he don't have to go far to find the fighting. there is a battle going on. ryan: we came to this bridge to film the destruction caused by the war. what we didn't realize was we are not entirely outside of the battle zone. [speaking russian] turns out i'm standing on top of a tank. he tells me not to move. he wants to check our documents. satisfied with our papers, he relaxes and we are free. next day, we were turned better

you mentioned biogen. drug bbibo-37 conference in nice gave data, cognition ratings, 71% reduction in decline. that's good news. >> yes. this is robust impressive terrific data. great unmet need in medical right now. and so the stock can go higher. i just have been telling people it started low 400s. will it go higher today than 30? probably, because this is remarkable. biogen first announced when the stock was 313. it not like you're early. but it is amazing data. >> we'll talk to meg tirrell about this in a moment. all over the story. yesterday you said isis pharmaceutical, for example. feel free to take some profits. >> i've been recommending isis the stock dropped, one drug that wasn't perfect, they have 13. it went from 71 to 63. twitter is an interesting thing because everybody buys at exact worst moment according to twitter which is moment you told them, so to speak, surrender. it went well above where i said to buy. i've been recommending it since 40. and the stock's up on the same news over and ov

look at biogen period. i mean biogen as i think, 9.5 waiting in the ibb. right?lzheimer's, the potential to be the biggest drug ever. trading at i think 26 times earnings? it's a home run. you can't find that anywhere else. money's going to continue to stay in this sector. >> you've been unequivocally positive with you and your analysts. ari, take out the emotion and all the 25 times, blah blah blah. are the charts overextended? what do the charts say? >> very r very overextended. if you haven't bought biotech by now, today's not the day to do it. we're very extended. one hand very extended most important averages. the long-term trend is there. i agree longer term is still a place to be. investmentwise, don't sell all your shares today either. buy it on the pullbacks. i have a feeling the ibb pulls back tots 50-day moving average marking a good opportunity to buy the etf that comes in around $350 after your support level. >> ari wald overextended, thank you both very much. >>> for more "trading nation" head to our website. two other original segments per day. i b

tomorrow biogen will shed light on its experimental drug for alzheimer's disease. the initial results of the drug were released in december. shares shot up in that company 40%. meg tirrell takes a look at what to watch for. >> reporter: biogen shocked everyone in december when it reported initial data from a small study examining the safety of its experimental alzheimer's drug. what people didn't expect is that it would show signs of working as well. tomorrow. additional data from the study reveals how strong the drug looks. >> we've had a few fits in starts here with alzheimer's drugs. this class especially we've had a couple of fairly high profile you know, call it failures. but i think what's got folks excited is it's a little bit different. >> reporter: known as bib37 appeared to clear the amyloid plaques in the brain associated with alzheimer's disease and looked to stem decline cognition in memory and thinking clearly. on the strength of the results, it would move the drug quickly into phase three clinical trials, the last stage before for approval. successfu

let's take biogen idec.for 20 years this mutual fund that i have owned for 20 years. it's i think the largest shareholder in biogen idec stock and it's the largest stock in the entire portfolio. >> but you wouldn't buy it here. >> i watched biogen stocks for ten years. from 2011 until today it has gone up eight fold. an eight fold increase means on a day like today there are people buying biogen stock at $475. they have put a value on this alzheimer drug alone of $10 billion. let me just finish. they are saying that i'm going to pay today $10 billion for this alzheimer's opportunity. now, i'm not going to say it's not worth it because alzheimer's is a huge opportunity but when you look at stock market charts that go parabolic the way biogen stock has done you always have to take pause. that's a classic sign of something overheated. >> i have seen many things go parabolic, but in the case of biotechnology today, what you really have to consider is some of the real results that are occurring. this summer at th

still up here which brings me to biogen idec. on friday we're going to get data on biogen's breakthrough alzheimer's drug. i think that everyone and his brother knows. this i think it is so obvious. plan is nose on my face. it's the most discounted new drug on the planet. the stock should sell off when the data come out. but everything i just told before you this indicates that won't be the case. you can actually buy some biogen here ahead of the data. and still make money. i don't know how that is possible people. i don't know how the stock market can be so stupid. biogen probably works even though it rallied at seven points today or 2%. the stock market is not doing the job. they're not taking into account breakthroughs. it's saying, no, no. it's okay. it's okay. so i guess it is not too late for any of these stocks. particularly biogen on the eve of the new alzheimer's formulation. extraordinary. it's not even biotech. there are others. pharma makes no sense to me either. not discounting correctly. last week when they made a p

so it's possible that the biogen antibody is just superior to the others.it's also possible the biogen trial design was the secret because they screened for people who had-- they used amyloid brain scans to select the subjects. so they knew that the people going in had amyloid in their brain. in previous trials, those folks with amyloid negative or with negative amyloid scans were included. so if they were not responsive to the medication, they would have diluted out the effect. so it's possible that if these other drugs are tested with the same design, they might prove successful. >> sreenivasan: all right, samuel gandy alzheimer's researcher at mount sinai, thank you very much. >> thank you. >> sreenivasan: and now to our signature segment, our original in-depth reports from around the nation and around the world. tonight, the battle to defeat isis. you've no doubt seen reports the past few months about efforts to stop young westerners traveling from the united states and europe to fight alongside the extremists. what you might not know is that some weste

biogen is a fabulous company.iotech in general is an outstanding industry, leverages the knowledge base of science and the innovations that are happening in geno micks. the industry is finding medicines that are, you know, solving medical needs. in the case of biogen a leader in multiple sclerosis, just had new very promising faze one data in all timers which is remarkable, so again, you think about the total opportunity in multiple sl multiple sler row discuss, strong in hemophilia and what could this company be earning in five years. in the case of biogen i think there's a good chance they will be earning much more money. again, even though the stock has performed well, the contrarian says wait a minute, the outlook is good, long-term investor says this is a management team executing exceptionally well and i'm willing to stay the course. listen, what's down? in terms of contrarian, energy has now fallen sharply, with the help of our research team at fidelity, i'm sifting through some of the carnage looking aroun

starting today biogen will simply be known as biogen. stock is lower thanks to teifel downgrade. it's up 15% in the past month. what's the trade? what do we think of this call one month, 16%. year-to-date the stock has been up 40%. you can make the case on a lot of these as the note says it's been a wild ride, time to breathe a little. couldn't you say that about a lot of the -- >> this is a great call by the steifel analysts. he is not saying there's anything wrong. he didn't put it at a sell. he put it at a hold. that was the reaction after you look at what the stock's performance has been. we talked about it for a while. i think there are names in biotech that are probably getting a little bit stretched. we've talked about that last week. that doesn't mean that some of the names don't have great pipelines still, and some of them traded at incredible valuations. biogen right now looks like it may be stretched. it doesn't mean this guy suddenly got negative on it at all. it's just -- >> we're not criticizing it. >> i'm saying can you ta

yes, biogen seems to have hit a rock 'em sock 'em alzheimer's drug.mulation, all 13 of them are very exciting. yes, i believe in receptos. yes, i like the future of immunotherapy. nevertheless, i love profits. i love making money. and a lot of money has been made. why not ring the register on some so you can try to play with some of the house's money? and not just your own. the bottom line no one has ever made a mistake taking a fat profit in the ten years i've been doing this show. and if you buy them here and you blame me then you are sorely wrong and have lost all focus. focus bag code word for you're a real chowder head. stay with cramer. attention investors!s! vectorvest mobile is here and it's free! make faster, smarter better trading decisions with ctorvest mobile. the most powerful app or managing your portfolio from the palm of your hand. only vectorvest mobile analyzes ranks and graphs... ...over 16,000 stocks worldwide, everyday,... ...and gives you clear buy, sell, hold recommendations... ...on every stock; anytime, anywhere. vectorvest mo

biogen and amgen have seen a lower death rates.ery much, at our breaking news desk. officials are expressing concern about the dollar. a wrote a policy knowledge inc. the soft dollar is the head went for growth. mgm resorts international rejecting proposed board nominees from an activist hedge fund manager. mgm rejecting all for director nominees, setting the stage for a proxy fight. and snoop dogg says he is developing hbo series while giving the keynote at sxsw. the former gangster rapper says that he is working on a show about 1980's los angeles. it is the talk of silicon valley. the gender discrimination lawsuit filed against a company. closing arguments are approaching. what are the broader implications of the case. to join me alix ruddy. alix, thank you for joining us. for those not familiar with the case, why is it so important? guest: it is important because ellen powell has taken the courage to stand up and talk about tiny cool opportunity in silicon valley. it is a problem going on for a long time and she has the courage

you know that. >> biogen. every night i said buy biogen. it's up 40. still buy biogen? for you? >> i -- my stock -- >> kentucky. biogen's kentucky. >> stock brokers say, no one taking a profit. you've got 16%, let's sell it. >> sell kentucky in the elite eight line. i'm going to hold it through. >> all right. i don't know. i don't know. kentucky against the field, i might take the field. we'll see. one of us will be right. >> when we come back this morning, many looks of paul macaulay, we'll ask if the beard is coming back in retirement. stick around. "squawk box" will be right back. in my world, wall isn't a street. return on investment isn't the only return i'm looking forward to. for some every dollar is earned with sweat, sacrifice, courage. which is why usaa is honored to help our members with everything from investing for retirement to saving for college. our commitment to current and former military members and their families is without equal. start investing with as little as fifty dollars. >>> okay. there's -- wow, that's a cool look on the left there. let get

tomorrow with biogen. that's phase one with them about the monochromal antibody.p there in the stratos fear versus biogwen. >>> tesla coe elon musk says hands free is own a few months away. so why did the stock sell off after the big vote of confidence? a deeper dive into what's behind that move. that's next. yes, when others focus on one thing, you see what's coming next. you see opportunity. that's what a type e does. and so it begins. with e*trade's investing insights center, you can spot trends before they become trendy. e*trade. opportunity is everywhere. >>> "fast money" live from the nasdaq. tesla has anxiety and is giving some investors anxiety about the stock. we have an analyst that says you should buy everything you can. >>> nike shares moving higher. a conference call about halfway through. the latest from the ceo. facebook, google and apple making payment sexy again. originals. ebay and paychex going head to head. you get the vote on twitter for which stocks move forward. please cast your vote. elon musk held a news conference and he addressed range i

all in a day when biogen was moving towards a cure for alzheimer's, if you will.n any event, take a look at this. this is important. this is the long-term basically a lot of no activity. we get stuck and then this epic run and now we are coming out of the top of the channel, which marks, of course, this very important period for biotech. we would fade, take profit, do something. >> all right. so mike, how are you trading? >> you know, this is an interesting case, because, what a lot of people are talking about is the search for growth. the biotech provided. take a look at the biggest constituent of the biotech index, for example, what you will find are names like celgene, gilead, biogen, which he mentioned. these are vaims names seeing double digit top line growth and we're not trading at ludicrous multiples a year ago. the others were up 60-70% off their one-year lows. >> that issue gets them to the same place the s&p is. which is while they were once cheap, they were pretty much fully valued if you look at their multiple to growth. i'm kind of in this camp with

i want to bring your attention to shares of biogen. in december they shocked wall street when it reported positive initial results on its alzheimer's drug. in the last 20 minutes the company released full data from the study. the drug exceeded expectations in treating the disease. you can read the full results on our website cnbc.com. let's also get you a run down of what to watch this trading day. the atlanta fed president is speaking this morning about the economy and monetary policy. at 1:00 p.m. eastern we get the weekly rate count report from baker hughes which tracks the number of riggs exploring for oils in the u.s. as for earnings look for results from tiffany and kb home. joining us to discuss more about today's trading action the author and founder of average joe options.com. pleasure to have you on. up one day, down one day, what have you made of this week's price action? good morning. the price action is typical of a nonvolatile market. but for trading there's not that much volatility. i also learned this week that the fed

biogen, ida. >> i'm in the big pharma names and not as much as bioteches because incredible pipelines and start looking into what they trade. biojen, just on the hope for something in these phase threes but i tell you what. it makes me nervous when i hear you say 20% down potential if things aren't so great. that's a pretty big hit to the stock. right? >> yeah, if you look at the items, come back to this. you just quoted, ibb up 17% to year-to-da year-to-date. but if you look at ibb, biogen is number one and then gilead and a.mgen. if you're in the name, you're going to shoot urs yo if it's up 25%. >> that's what -- >> i've been playing the sis si way up a long, long time. fdt and fbl. >> after the break, big day for alibaba. the stock holding on to gains into the close, so it's bottomed out. mark maheni in the house. where might the real value lie in the market? our own bk dives into one active class you should be buying into. that's next. >>> still ahead on "fast money," the fed fueling a major

you mentioned how biogen's drug was the stock yesterday. >> yeah.uld announce before the open today, michelle, and also knew this was a phase one trial. so you don't usually get this kind of news in a phase one, because they're actually in this case talking about how effective it was not just whether or not it's safer and so that was one of the reasons that the stock just exploded, i think it hit a new all-time high of $478 a share. this one's on an absolute tear, and still looks like it's got significant ramp ahead of it. >> hold on. wait. that's got -- significant ramp but espr doesn't? >> more drug, stephen. >> come on. >> more things in phase one, phase two, phase three than espr. >> i wouldn't trash talk it. you might need the drug. >> i'm not trashing them. >>> move on to today's worst trade. is calorie counting your alcohol consumption? do you want to mow the nutritional stats in your guinness? smer no smirnoff or johnnie walker? displaying information on labels and online. yes, nutrition labels on your liquor. the u.s. will likely be the fir

across there, look at what's been going on, j&j over $100 a slayer, some of these biotech names, biogengilead, amgen, you get yield in many of the various parts of that market in health care, unh, some of those, but you also have companies who have plenty of growth in front of them. >> josh, looking at no follow through in the dow from yesterday but the nasdaq manages to hang op. what are your thoughts on this day after janet yellen. >> >> i think a lot of people saw the late day rip in the euro versus the dollar and took that to be signaling something. at the end of the day it was a counter trend move and i think a lot of the prevailing trends from this year so far are still in force. health care and it tech still look better than most of the market. utilities are showing the same strength they normally do when bonds act well and at the end of the day it's growth versus value and it's russell doing much better than the s&p and that has not changed at all. >> to be clear you're talking about right after the fed statement or the post 4:00 move in currencies where you saw two-second rip.

nasdaq biotech index up 240% since 2012 and the biggest names, gill he ad, up 40%, amgen up 40%, biogenp 47%, celgene up 75%. >> you can understand why the stiefel analyst on monday when we talked about this on the show why there was hesitation and pause and came down to a hold position on biogen. when you look at some of these names they have taken off. it's been an incredible run. you could have said the same thing three years ago, wow, this thing is in a bubble, last year, these things have been moving to the upside when you look at a lot of these names. the moves have been extremely sharp. a pause maybe a bit of a rotation, but to josh's point i don't necessarily think that biotechs are going to be the bubble that bursts the market. i think it's a rotational market right now and we're starting to see more and more of it come out of the bioteches into other areas. >> unless, you know, selling begets selling. steve, you play a lot in this space. >> yeah. i'm definitely involved in the space. look, i'm conflicted a about it personally because i think if you point out gilead, for exampl

biogen shares are rising after the company's experimental drug for alzheimer's showed promise. in an early stage trial, the drug slowed progression of the disease, showing progress in two key areas. biogen is skipping mid-stage testing and moving to final stage trials that will begin later this year. now, to the lead. a gender discrimination trial is taking a new twist. matt murphy testified that he pleaded with ellen pao to improve her performance. murphy said pao was prone to conflict said did not respond to his advice. his first notes were dated days after pao filed her lawsuit. katie you were at the trial yesterday, i believe? what was it like? katie: the trial has been interesting almost every single day. the defense has done a very good job of painting ellen pao is a difficult employee. her story is that she was not only discriminated against, but it was generally an unfriendly place for women to work. she did a good job of establishing that case. they had a great witness. she talked about how she had been sexually harassed and how poorly the firm handled that. that was g

bill: biogen now has and also -- now has an alzheimer's drug.at is good news for science in these patients, we want to be apart of. we have an awful lot going on it in type two diabetes, and oncology ourselves, targeted therapies, small molecules combinations. stephanie: what does obama care mean for you? paul: we are passionate about where the health care dollar get spent,. anything begets access to medicines as a patient is a good thing. we're trying to work with payers and providers to get the best value for the dollar. bill: i always wanted to ask this question -- how do you come up with the names for these drugs? stephanie: i'm with him on that. your new drugs such as -- that just got approved -- stephanie: there's not even vowels in those names. paul: naming pharmaceuticals is a complex and difficult challenge. there is a lot of names out there and we have to pick names that are easy for patients to understand. stephanie: there is one with seven x's in it. paul: the research helps us to understand that patients will understand that that --

biogen idec shares soaring today.et's go to nicole petallides on the floor of the new york stock exchange with news on this one. look at that chart. >> wonderful chart. with a wonderful breakthrough melissa. right now the stock is up about 9 1/2%. 475.06. hit a new high. a winner this year. this is about alzheimer's. when you talk about alzheimer's. by the year 2030, 75 million people will actually have alzheimer's and need effective treatment. they have found treatment now that does something never been done before. it is experimental drug. it reduces plaque that can be brain damaging, while at the same time, significantly slowing cognitive decline. so that is a great double dish. and that is why you're seeing this big move to the upside in a new high for biogen idec. back to you. melissa: nicole, thank you so much. i want to bring charles payne on this one. you've been pounding the table on this stock on your fabulous 6:00 p.m. program. >> yes. melissa: are you taking a victory lap. >> we'll take a victory lap and g

check out biogen.o hold after a 10% gain on the back of exciting data for its experimental alzheimer's drug. the stock still up 40% so far this year. nearly double what the nasdaq has returned. stifel saying that's too rich to expect more growth and noting two biodgen's key programs and one multiple sclerosis. don't have expected catalysts for the next 18 months. now, on top of that stifel points out an ongoing patent dispute of the -- not everyone agrees. on friday they came out six analysts raised their price targets on biogen's stock. there's still a lot of optimism there. on the flip side a positive move for pfizer. the drug giant was added to the franchise picks list at jeffries which raised its price target from $3 to $45. it says it expects pfizer shares to appreciate significantly in the next year or two on a fast lodge of its new breast cancer drug i brands. the groh of its established products and proteshl splitting off of that business in 2017. now, remember pfizer just spent about $16 billi

biogen now shortening its name to biogen. a decade ago creating one of the world's biggest biotech companies. its shares coming down from record highs. get it? after announcing a new drug to treat alzheimer's. radio shack is being decided at a bankruptcy auction. one offer wants to keep the brand up and running, but on a much smaller scale. other parties want to sell off all remaining inventory and close the business for good. what will happen to those ads? wilson sporting goods is buying the louisville slugger brand for $70 million. all rights will now go to wilson. that's the latest on the fox business network giving you the power to prosper. ♪ >> march madness living up to its moniker with no shortages of upsets. wichita state knocked them off. the shockers. i learned what that means. moving to notre dame. i'm from the city. what do you want? they may never stop partying in wichita. it wasn't an upset. that didn't stop top speed doing back flips after cruising over iowa. getting into the act with a handstand, the coach. ei

biogen, the biogen biotechnology giant is surging nearly 10% right now after positive face one drug tests results for alzheimer's drug came out and investors have reason to celebrate. if the drug gets regulatory approval could generate from $4-20 billion in annual sales. they called the blockbuster drug 1 billion dollars in sales. could this be four or more. >>> not losing patience with activist investors yet but appears the sec might be getting close to losing patience. mary jo white criticizing shareholder activism in a recent speech issue anding a warning to be careful. charlie gasparino believes this was pointed at one particular activist. >> our favorite activist. the guy that makes the news all the time. liz: bill ackman. >> that's what we like about bill, he's controversial, interesting. takes on good cases. liz: makes money. >> he doesn't talk to me. that's all right. small things like that. wharf happened is mary jo white, the sec chairman gave an interesting speech at tulane university at the law center. two issues, the deal that ackman did when he went after the company valiant

gilead amgen, celgene, and biogen. biogen 4.5%. the smaller ones are really really harder hit. them all down almost double digits. the rest above 10%. clearly a lot of pain going on. it's been a tough week for biee tech biotech in general. it's been a losing streak for three weeks. it's causing a lot of jitters about whether the biotech run up 280% in the last five years could be ending. a lot of disagreements about that, but clearly a lot of fears today. back to you guys. >> all right, meg, thank you very much. let's talk more about this sell-off in biotech specifically right now. >> joining us now is les and barbara ryan. barbara, do you look at this space and sense opportunity or is it still looking pretty risky? >> i mean, i think you have to look at this selectively. i think meg pointed out the great performance of the sector and i think it's important to note that this is really being driven by fundamentals. number one, strong topline, bottom line growth. a lot of capital going into the space. by the same token, everything has gone up in the sector and i think investors a

drug maker biogen released findings today. it shows the drug may slow memory loss in alzheimer's patience when the disease is still in a mild stage and reduces the plaque in the brain associated with alzheimer's. a much larger study is needed to confirm the results. >> call it an extreme case of the scenic route. four family members took off from stockton and headed to the park yesterday. after driving six hours they were loss on the dirt road in the middle of the forest so they called 911. sheriff deputies said families smoke very little english, using the ping from their cell phone and pictures that they texted deputies found them and helped them find their way back to the highway. the family smentpent nearly 24 hours tropical storm andrea stranded. >>> a cosmic phenomenon marks the first day of spring. millions of people all across europe stop to enjoy a solar eclipse that streaked across the skies. the rare total eclipse could be seen if certain spots in norway and lasts for less than three minutes. the rest of europe saw

some saying the high-flying sector is potentially starting a correction, biogen, celgene all getting hit and lerszs known, infinity pharma, should we be worried about this area of the market which has helped push the nasdaq to new highs? >> on friday i think it was, you pointed out, that huge run-up in the ivp, reverse close lower, and it's come to fruition. huge sell-off today, down 4%. i still think biotech's in a nice uptrend. if you look back to may, we've had sell-offs of this magnitude a few times since then. but ivp through 320 might change the course of direction. i'm still a believer in biotech, but the trend has been your friend. i think it continue to be. >> 3320 would be a big deal because 335-ish has been good support. >> and think we have seen on volatile days we've moved through this. if you look at the underlying stocks, top weights biogen, amgen, celgene, this makes up about 40% of the index right there. if you look at some of those stocks, all those are not created equal. amgen looks the most defensive. reasonable value but a stock that's been trapped in this range

it almost closed in the red having been up substantially higher in a day that biogen was apparently moving towards a cure towards alzheimer's if you will. in any event, now, take a look at this. this is really important. this is the long-term basically a lot of no activity. we get stuck. this epic run. now we're coming out of the top of the channel which marks, of course, this very important period for biotech. we would fade, take profits, do something. >> all right. mike, how are you trading this? >> this is an interesting case. of course, what a lot of people keep talking about is the search for growth. biotechs had provided. take a look at the biggest constituents of by okay tech index, sellgen, gilead, seeing double digit top line growth, double digit eps. up 60, 70% off one-year lows. that issue gets them now to the same place s&p is. while they were once cheap now fully valued if you take a look at their multiple to grow. i'm kind of in this camp with carter here thinking while it's a very good story in most of these cases the valuation makes it tough to chase. i think what we're goi

if you look at the biggest names, amgen, celegene and biogen.r names that you have highlighted a lot that are seeing the biggest losses today. novavax, newly genetics and leading the index lower. other names really we're just hearing about a lot of fear in the space. this three-day losing streak is the longest for the nasdaq biotech index since february 4th. i've been talking with a lot of investors, a lot of industry folks just about what's going on here. is this a bubble? are we seeing the end of it? are we seeing the end of the rapid rise? the nasdaq biotech index over the last five years is up 280%. this is really go go go. what a lot of people are saying is this is a lot of fear coming in. this is three days this week. then it's been bad. that's playing in here. a lot of other folks say it's about whether you think the valuations are too high. is this ending or coming to an end, and there are arguments there. people say say these are worthy based on the profits and revenues and promise of the people liens. other folks say this is crazy no m

biogen will likely be splitting if the drug is successful.with the 9% stake. the stocks fell. there is a report this morning high -- hont han hai will be proposing this as early as next month. a spokeswoman for sharp they thickly saying if foxconn wants forestart talks investment at 550 in a share, startre prepared to talking. they have received a formal request. it's up to you. last, we look at three holdings. we are up 5.5%. dividends, buybacks, and they are racing the for your dividends from five into seven yen. away from japan, two in taiwan and one in south korea, reflective of what is happening. 6%.top a record high for the second straight day. analysts,cross 29 overwhelming by. -- buy. pou chen a drop in profit. in south korea dropped. that is according to one analyst covering the stock. back to you. >> we're going to have a look. singapore's first prime minister. for many the name is synonymous with the birth and development of the city state. kuan yew is often called singapore's founding father. during his more than three singaporee,

these three stocks biogen rementioned before.been driving the nasdaq. they're some of the largest market cap companies there. becky, if you look at what's happening overall with the market some large cap stocks especially headache have been driving things forward in the s&p over the last week month, and year to date. health care stocks have been the standout. >> thank you. again, dom chu. >>> dallas federal reserve fed president richard fisher had tough words for market participants last week. >> what worries me however, is how lazy investors have gotten. totally dependent on the federal reserve. i find this to be a precarious situation. but all i'm saying is right now in terms of the real economy, we are growing, others are not growing as well as we are. we're still innovateing and inventing. >> let's get one of our squawk market masters to weigh in on this as well. peter fisher is also a senior fellow at the tucks school of business. those are tough words. investors are lazy at this point. would you agree with that? >> no i don

jeffries is saying they may share equally with biogen.are targeting 20% shareholder return from the next fiscal year. remember those in talks back in 2012. the stock basically collapsed to the level we're at right now. report this morning they may hold investments. a spokesperson commenting on the issue. she is basically saying if foxconn does want to restart talks at ¥550 and share then sharp is prepared to talk. the other big movers. the fourth day of gains. we are looking at a price target of 362 taiwan dollars. i will leave it there. back to you. rishaad: i am joined by zeb. i can't start without mentioning lee kuan yew and the towering hero he was. >> absolutely. among the chinese population worldwide i think when somebody dies at an old age it's not just a cause to be sad but to celebrate. there is a lot to celebrate. rishaad: he does have this legacy. what a legacy to have. >> there are two independent nations that have become modern nations. that's his legacy. it's amazing. it's astonishing. if you look back to 1966, that would ha

biogen and popped on news for alzheimer's disease look at the stock the news took it from phase one of the phase three development everybody seems to be jumping on the of bandwagon. this is the old target everybody says it could be a $500 stock all the big names out there but here is the beautiful thing. you had a first we have been talking about the stock and we will follow what because biotech is still hot. everybody wants to live to be 120 without pain and agony and this will get us there. speaking of longevity the rally picked up speed we could be on the cusp of a major breakout for the indices' in debt will be big news on main street but first let's check in with nicole petallides that new york stock exchange. >> you are right to another rally on wall street. individual investor should they be investing for the long term? >> can rally is remarkable because one week ago i was nervous and a negative and i suspect i still m but you cannot fight the tape and it is spectacular today. >> what about the regular person? it is tough to stomach to make the interesting question we have a lot

biogen after being downgraded by steeple and vretex shares lower after disappoint oing results for atic fibrosis drug. over the fast year it's up about 40%. >> very very strong performance. let's switch focus to a sector that's not done so well over the medium term. big oil and gas producers and another one is tight bening it's belt. let's get to landon with more on the story from cnbchq. >> good morning to you. chesapeake energy is the latest energy company to cut back amid lower global oil prices. the oklahoma city based firm is slashing it's 2015 capital budget by more than 10% and sharply cutting it's production outlook. the move comes in response to continued weak commodity prices. prices dropped 50% since last june as growing supplies from oil sands in north america are overwhelmingly weak global demand. the second largest gas producer places it between 3.5 and 4 billion this year down from 4 to 4.5 billion. it also plans to operate 25 to 35 riggs. less than half the number from last year. chesapeake is cutting it's production target to between 1 and 3% growth in 2015. last yea

seven shares of biogen have earned 30% in six months. you are the man, charles. thomas, you're the man. perfect timing on that email. thanks a lot. that brings us to our next real, real deal. i've spent the last seven or eight months doing this show trying to help people get into the market. these are some of the obstacles. >> this is the biggest question i get. why are we buying a stock for $200. and buy ten times the share for $20. yes, it has to go up $10. that's a 5% move on a 200-dollar stock. same thing -- it's all about percentages. if you're investing $200 in a stock, it's about percentages returned. it's doing good if it's trading at $200. >> you have a newsletter. really popular. you feel pressured. for me -- when i get out of a stock too early. i admit that. do you feel pressured to focus on stocks that look cheap even though they're not cheap, like, i.e. the price. >> well, what we do is try to find the stocks under $10. but we've come to the conclusion that you really have to stay away from the penny stocks. stay away from the biotechs that are binar

we got amazing results out of a new class of anti-cholesterol drugs and biogen had a study that coulduce alzheimer's and taken up in the wake of this terrific news flow. the overheated companies didn't issue a lot of equity when they were up there and a bubble of sorts has been become evident in small drug developers with phase one and phase two compounds that may never pound out. the ability to stabilize yesterday and rally today after the smackdown, what can i say? it's definitely a positive sign. nothing like a little activity rumored to gaffe the short sellers and get the juices going. is there a bottom in biotech? i call it enough -- i would say a much needed shakeout that's running its course. we saw a parallel crushing of the best of the semiconductor stocks, the ones the with the most content link to cell phones and connectivity nxp semiconductors, there's been carnage for months that accepted those but there's real blood letting in intel, micron companies like intel and micron are seen as too linked to personal computers. they don't have the leverage to connectivity that the

an early testing, a new drug from the company biogen showed a slowed rate of mental decline in alzheimer'scomes with several side effects including brain swelling further testing is being done. >>> finally, a real-life ghost driver getting ready to cross the country, a cross country journey, the self-driving audi self-driving audi will set out from the golan gate bridge tomorrow to new york city. it's loaded with sensor computers and cameras that can read lanes, road signs and traffic lights. there will be a person a real human being inside that vehicle as it travels the 3500-mile route. that person is so to speak just along for the ride and is not supposed to touch any of the controls. >> can it parallel park? that is the big question? >> we will find out when it gets to new york city. >> hey, rob. >> the tie on and suit. >> how is the weather. >> i'ms only going to miss winter. >> really? >> all that time you spent in boston covering snowstorm after snowstorm. >> you know what they say at disney, the coal never bothered me anyway. >> ba-dum-dum. >> somebody call the bosses. miami beach,

drugmaker biogen released its findings from a small study.cates the experimental drug may help slow memory loss in alzheimer's patients when the disease is mild. it reduces the plaque in the brain that is associated with alzheimer's. headaches and brain swelling are some of the side effects. doctors say much larger studies are needed to confirm these results. >>> much more ahead on "today in the bay." coming up, we investigate pg&e, has it done enough to improve security after this shooting at a power station two years ago? >>> you're watching "today in the bay." >>> welcome back. 7:50 on saturday morning. a foggy look at the golden gate bridge. cooler today across the bay area. a mix of sun and cloud. as we look in downtown san jose, same thing. low cloud fog coverage. it will be cooler saturday like i said. but still quite lovely on this second day of spring. it was an attack that moved san jose into the national spotlight. an attack on a pg&e sub station. the unanswered question -- was it a trial run by potential terrorists. now pg&e has m

>> i think when you talk about getting off the gas right now, look at biogen. look at the move it just made. this stock was up 40% in a short period of time. still up around 35%, 36%. yes, some of these names i think are they over-extended? probably a little bit. i think this is very disciplined in the terms of the downgrade today after the move it's made. when i look across at the biotech names, i still look at them and look at a pe with the exception of one all underneath 20. these are real stories. they have pipe lines but also real earnings. these are companies i think you could still own. you don't have to chase them, but i think you could own all of them. >> it's impressing how they're doing. we had a bullish call on pfizer this week. so it's not just bioteches. it's also more broadly pharmaceutical companies. >> pfizer since the acquisition, they seem to have their act together in terms of the stocks. just in terms of pete said now. we get a lot of pushback, biotech in a bubble. 35% have little or no earnings. i think we all understand that. but to pete'

in this small study from drugmaker biogen it slowed memory loss in people just starting to show symptoms. experts in the alzheimer's field are optimistic about the findings but urge caution. >> this is very early in those human clinical trials. it will be going to its next phase where often we've seen these drugs fail. >> the alzheimer's community is buzzing about an experimental drug which is showing great promise again in early research. again, more than 5 million americans living with alzheimer's. no drugs, no therapy. the doctors say this experimental drug may benefit mills s millions of others in the earliest stages. >>> even though the cherry blossom festival has begun, there will be track work on metro this weekend. trains on the orange silver blue and yellow lines will operate every 18 minutes this weekend. the red and green lines will have a regular schedule. usually track work is suspended during this festival but this year metro decided to continue track work for the first two weekends. >>> a community fixture left in ruins. now there's a new snag in the plan to get a local la